A Veracyte Insider Sold 24,000 Company Shares for $1.1 Million. Here's a Deeper Look at the Transaction.

Robert Izquierdo, The Motley Fool

Sat, July 4, 2026 at 6:25 AM PDT 4 min read

Jonathan Wygant, Vice President and Chief Accounting Officer of Veracyte (NASDAQ:VCYT), reported the exercise of 24,000 options and immediate open-market sale of the same number of shares for a total transaction value of approximately $1.09 million, according to the SEC Form 4 filing dated May 27, 2026.

Transaction summary

Transaction value based on SEC Form 4 weighted average reported price ($45.40); post-transaction value based on May 22, 2026 market close.

Key questions

• What is the nature of this transaction and how does the derivative context affect interpretation?
  This event involved the exercise of 24,000 fully vested options, immediately followed by the sale of the resulting shares, which is a common mechanism for insiders to monetize awards without increasing outright equity exposure.

• How did this sale impact Jonathan Wygant's ownership position?
  The transaction reduced his direct ownership by 34.57%, from approximately 69,000 shares to 45,434 shares, with no remaining indirect or derivative holdings reported.

• How does the transaction size compare to past selling activity?
  This was materially larger than his last disclosed open-market sale (10,920 shares in November 2025) and, given the shrinking holding base, constitutes a larger proportion of his available shares.

• What is the implication for future capacity and potential insider activity?
  With just over half of the prior-year holding remaining, future sales are likely to be constrained by reduced share capacity unless new awards are granted or vested.

Company overview

* 1-year performance calculated using May 22, 2026 as the reference date.

Company snapshot

• Veracyte offers genomic diagnostic tests for cancer and other diseases, including Afirma, Decipher, Prosigna, Percepta, Envisia, and Immunoscore, with a focus on thyroid, prostate, breast, lung, and colon cancers.

• It generates revenue primarily through the sale of molecular diagnostic tests and technology licensing, leveraging proprietary genomic classifiers and collaborative partnerships.

• The company serves healthcare providers, hospitals, and clinical laboratories globally, targeting clinicians involved in cancer diagnosis and treatment decision-making.

Veracyte is a diagnostics company specializing in advanced genomic testing for oncology and other diseases. The company leverages proprietary technology and strategic collaborations to deliver diagnostic solutions that help reduce unnecessary procedures. Its diversified portfolio and global reach enable it to serve the precision diagnostics market.